ANTEROGEN05 INVESTORS & NEWS
IR & News
Anterogen discloses key management updates, notices, and regulatory filings with transparency.
NOTICE ARCHIVE96 POSTS · UPDATED 2026.08.07
All Notices
96 postsNotice
Japan sales status
→NoticeWe would like to inform our shareholders.
→NoticeWe would like to inform our shareholders.
→NoticeWe would like to inform our shareholders.
→NoticeWe would like to inform our shareholders.
→NoticeDear shareholders, you have waited a long time.
→NoticeAllostem clinical trial results
→NoticeWe would like to inform our shareholders.
→NoticeInformation on Japanese insurance registration for “Allostem Sheet,” a regenerative medicine product
→NoticeWe would like to inform our shareholders.
→NoticeInformation on progress after approval of Allostem in Japan
→NoticeNon-clinical toxicity test results poster released for new drug candidate for shingles (POM-L-BHDU)
→NoticeDevelopment status of POM-L-BHDU
→NoticeProgress status of ANT-301, a treatment for degenerative arthritis
→NoticeAllostem insurance drug price listing time
→NoticeJEB, this is a really unfamiliar disease!
→NoticeWe would like to inform our shareholders.
→Notice[Press release] Anthrogen ‘Allostem’ obtains product approval from Japan’s Ministry of Health, Labor and Welfare
→NoticeFirst approval for skin regeneration stem cell treatment in Japan (Korea Economic Daily)
→IRHeld a corporate briefing session (IR)
→General Meeting of ShareholdersAnnouncement of convocation of the 26th regular general meeting of shareholders
→NoticeWe would like to inform our shareholders. (Regarding the holding of the Allostem licensing committee)
→NoticePMDA review in progress
→NoticeRequest for additional data related to PMDA’s CRO audit
→Noticeovercome important obstacles
→NoticeReport on PMDA permit progress to date
→NoticeWe would like to inform our shareholders.
→NoticeDegenerative arthritis treatment (ANT-301), continuous improvement for one year from one injection
→NoticeDevelopment progress status of shingles treatment
→NoticeWe would like to inform our shareholders.
→Notice(Reporter Seo Han, Yonhap News) Hope opened by new drug “Taibaso”
→Notice(Reporter Seo Han, Yonhap News) “Taibaso”, why did you ignore patients?
→NoticeDegenerative arthritis treatment drug (ANT-301), treatment effect confirmed in severe KL grade 4
→NoticePOM-L-BHDU-US continuing patent registration
→NoticeDevelopment status of POM-L-BHDU for the treatment of shingles
→NoticeNotice to shareholders
→NoticeSelected as a pan-ministerial regenerative medicine technology development project in 2025
→NoticeAntrogen R&D major progress status
→Audit ReportAnnouncement of the 25th audit report (2024)
→Business ReportAnnouncement of the 25th (2024) business report
→NoticeRegistered as Korea's first cell therapy manufacturer recognized by the Japanese Ministry of Health, Labor and Welfare
→NoticeDegenerative arthritis treatment drug (ANT-301) clinical progress status
→General Meeting of ShareholdersExercise of voting rights for written resolution by shareholders and solicitation of voting rights by proxy
→General Meeting of ShareholdersAnnouncement of convocation of the 25th regular general meeting of shareholders
→NoticeInformation on the development status of shingles treatments
→NoticeOsteoarthritis phase 1 clinical trial progress information
→Notice“Sheet-type 3D cultured stem cell therapy” registered as a European patent
→NoticeEuropean patent registration for manufacturing method of injectable 3D cultured stem cell therapy
→NoticeMortonton hair loss relief functional cosmetics approved
→NoticeRegarding the Mortonton-S special edition
→NoticeInstructions on how to use Mortonton-S
→NoticeYouTube video on how to use Mortonton
→NoticeHair loss relief functional cosmetics Mortonton
→NoticeMortonton YouTube video (Director specializing in hair loss treatment)
→NoticeTaibaso product approval
→NoticeExplanation on why DEB disease treatment development is focused on Japan
→NoticeDEB phase 3 clinical trial progress update
→NoticeHerpes zoster and herpes simplex treatment candidate material presented at ICAR International Conference
→NoticeRecruitment of healthy donor fat tissue extraction research subjects
→IRSharing answers to IR inquiries
→NoticeAnnouncement of 24th financial statements
→IRWe provide information regarding IR response.
→NoticeRegistration of the first patient in the U.S. DEB phase 2 clinical trial
→General Meeting of Shareholders제24기 정기주주총회 대표이사 인사말 안내
→NoticeCompletion of phase 3 patient registration for Japanese dystrophic epidermolysis bullosa (DEB) treatment
→General Meeting of ShareholdersRe-information on the exercise of voting rights and proxy exercise of voting rights for shareholders to make written resolutions
→General Meeting of ShareholdersRe-announcement of the 24th Annual General Meeting of Shareholders
→General Meeting of ShareholdersExercise of voting rights for written resolution by shareholders and solicitation of voting rights by proxy
→General Meeting of ShareholdersAnnouncement of convocation of the 24th regular general meeting of shareholders
→Notice"Remodulin® Injection, the secret of birth, old age, illness and death on KBS - aired as a new drug for pulmonary hypertension
→General Meeting of ShareholdersAnnouncement of the closing period of the shareholder list or the base date for confirmation of rights shareholders for the 24th regular general meeting of shareholders
→NoticeReport on Japanese DEB phase 3 progress
→Notice"타이바소 신속심사 의약품 지정"
→General Meeting of Shareholders(24th Extraordinary General Meeting of Shareholders) Written proxy for recommendation to exercise voting rights by proxy
→General Meeting of Shareholders(24th Extraordinary General Meeting of Shareholders) Voting rights exercise form for shareholders’ written resolution
→General Meeting of Shareholders(24th Extraordinary General Meeting of Shareholders) Convocation Notice
→NoticeDiabetic foot ulcer treatment clinical trial progress
→NoticeDEB (Epidermolysis Bullosa) clinical progress
→Notice(Korea Economic Daily) Antrogen, stem cell degenerative arthritis drug applied for domestic phase 1·2a plan
→General Meeting of Shareholders(Notice) Announcement of setting the base date for the extraordinary general meeting of shareholders
→NoticeJoo Joong-kwang, Distinguished Professor at the University of Georgia, "I will dedicate the rest of my life to leaving behind a new drug that can be widely used by the world"
→NoticeAntrogen expands beyond cell therapy and into the small molecule field
→NoticeWe would like to inform our shareholders (European DEB usage patent acquired)
→NoticeAntrogen, preclinical results for shingles treatment announced at international conference (Korea Economic Daily)
→NoticeAnnouncement of 23rd financial statements
→General Meeting of Shareholders23rd Annual General Meeting of Shareholders Video Broadcast
→Audit Report23rd (2022) Audit Report
→Business ReportAnnouncement of the 23rd (2022) business report
→General Meeting of ShareholdersWritten proxy for proxy exercise of voting rights
→General Meeting of ShareholdersVoting rights exercise form for shareholders’ written resolution
→General Meeting of ShareholdersNotice of convocation of the 23rd regular general meeting of shareholders
→General Meeting of ShareholdersMatters of holding the 23rd regular general shareholders' meeting
→General Meeting of Shareholders(Notice) Announcement of setting the base date for the extraordinary general meeting of shareholders
→General Meeting of ShareholdersNotice of convocation of the 23rd regular general meeting of shareholders
→General Meeting of ShareholdersNotice of convocation of the 23rd regular general meeting of shareholders
→General Meeting of ShareholdersMatters of holding the 23rd regular general shareholders' meeting
→No results found.
LEGACY NEWS1 POST
Legacy News
1 postHISTORICAL Q&A2013 ARCHIVE
16 Historical Q&A
Legacy Q&A from the previous website, preserved as historical records.
DISCLOSURE FIRST
Regulatory
Filings.
Anterogen's latest disclosures on business, financials, and governance are published through KIND and DART.